** Shares of drug developer AnaptysBio ANAB.O surge 28.3% to $15.88 in morning trade
** Co says its experimental drug, rosnilimab, met the main goal in a mid-stage trial for the treatment of rheumatoid arthritis, a chronic inflammatory disease that primarily affects the joints
** The main goal was to evaluate if the drug could significantly reduce symptoms in three dosages using a tool called DAS-28 CRP score, which measures the severity of the disease after 12 weeks in comparison with placebo
** ANAB says that the drug will be tested in patients with a type of bowel disease called ulcerative colitis by the second quarter of this year
** Stock fell 46% in the last 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。